Recent advances in the management of adult myositis

Expert Opinion on Investigational Drugs

Volumn 10, Issue 7, 2001, Pages 1265-1277

  Fam, A G ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Azathioprine; Corticosteroid; Immunomodulator; IVIG; Methotrexate; Myositis

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C5; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; CYTOTOXIC AGENT; ETANERCEPT; FLUDARABINE; FOLINIC ACID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5G1 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYOSITIS; DRUG COST; DRUG MEGADOSE; DRUG PULSE THERAPY; HUMAN; IMMUNOMODULATION; LEUKAPHERESIS; LUNG TOXICITY; LYMPH NODE IRRADIATION; MYOSITIS; NAUSEA; PATHOGENESIS; PLASMAPHERESIS; POLYMYOSITIS; REVIEW; SIDE EFFECT; STANDARD; THYMECTOMY; WHOLE BODY RADIATION;

ADULT; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HUMANS; MYOSITIS; PHYSICAL THERAPY MODALITIES;

EID: 0034941583     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.7.1265     Document Type: Review

References (62)

1. Classification and diagnostic criteria for polymyositis and dermatomyositis
2. Idiopathic inflammatory myopathies
3. Idiopathic inflammatory diseases of muscle
4. A therapeutic update on dermatomyositis/ polymyositis
5. Current approach to the treatment of polymyositis and dermatomyositis
6. Treatment and investigation of idiopathic inflammatory myopathies
7. Prednisone and azathioprine for polymyositis
8. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis
9. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
10. Treatment of inclusion-body myositis with IVIG: A double-blind, placebo-controlled study
11. Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens
12. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis
13. Pathogenesis of idiopathic inflammatory myopathies
14. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy
15. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: Current concepts of diagnosis and pathogenesis
16. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies
17. New developments in the role of cytokines and chemokines in inflammatory myopathies
18. Increased expression of interleukin 1 α and MHC class I in muscle tissue of patients with chronic inactive polymyositis and dermatomyositis
19. Inclusion body myositis
20. Idiopathic inflammatory myopathies
21. Creatine kinase activity inhibitor in sera from patients with muscle disease
22. The treatment of myositis: How to approach resistant disease
23. Functional outcome of myositis patients: Can a low-dose glucocorticoid regimen achieve good functional results?
24. Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy
25. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy
26. Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone therapy
27. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate
28. The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis
29. Cyclosporine, FK-506, rapamycin, and other immunomodulators
30. Cyclosporine A therapy in refractory juvenile dermatomyositis. Experience and long-term follow-up of 6 cases
31. Cyclosporine A in the treatment of refractory adult polymyositis/ dermatomyositis: Population based experience in 6 patients and literature review
32. Cyclosporine A as first choice therapy for dermatomyositis
33. Tacrolimus in refractory polymyositis with interstitial lung disease
34. A pilot study: Use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures
35. Intravenous immunoglobulin in rheumatic disease
36. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases
37. Intravenous gamma globulin as first-line therapy in polymyositis and dermatomyositis: An open study in 11 adult patients
38. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: Clinical responses and effect on sIL-2R levels
39. Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis
40. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents
41. Resistive exercises in the rehabilitation of polymyositis/ dermatomyositis
42. Role of rehabilitation in the management of myopathies
43. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: A pilot study
44. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy
45. Inclusion body myositis: Explanation for poor response to immunosuppressive therapy
46. Inclusion body myositis: Treatment with intravenous immunoglobulin
47. Safety and efficacy of strength training in patients with sporadic inclusion body myositis
48. Response to total boy irradiation in dermatomyositis
49. Thymectomy in refractory dermatomyositis
50. Chlorambucil: An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis
51. Effect of levamisole treatment in polymyositis patients
52. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen disease
53. Intravenous pulse cyclophosphamide in the treatment of lung disease due to collagen vascular diseases
54. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis
55. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: Prediction and treatment with cyclosporine
56. Cyclosporine treatment for polymyositis/dermatomyositis: Is it possible to rescue the deteriorating cases with interstitial pneumonitis?
57. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin
58. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions
59. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases
60. Basic calcium phosphate (calcium apatite) crystal disposition diseases
61. Intravenous immunoglobulins as treatment of life-threatening esophageal involvement in polymyositis and dermatomyositis